ATXS
Price
$5.21
Change
+$0.01 (+0.19%)
Updated
Apr 24 closing price
Capitalization
294.02M
13 days until earnings call
PHAR
Price
$8.58
Change
+$0.31 (+3.75%)
Updated
Apr 24 closing price
Capitalization
580.67M
13 days until earnings call
Ad is loading...

ATXS vs PHAR

Header iconATXS vs PHAR Comparison
Open Charts ATXS vs PHARBanner chart's image
Astria Therapeutics
Price$5.21
Change+$0.01 (+0.19%)
Volume$1.4M
Capitalization294.02M
Pharming Group
Price$8.58
Change+$0.31 (+3.75%)
Volume$1.53K
Capitalization580.67M
ATXS vs PHAR Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. PHAR commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and PHAR is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ATXS: $5.21 vs. PHAR: $8.58)
Brand notoriety: ATXS and PHAR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 399% vs. PHAR: 26%
Market capitalization -- ATXS: $294.02M vs. PHAR: $580.67M
ATXS [@Biotechnology] is valued at $294.02M. PHAR’s [@Biotechnology] market capitalization is $580.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whilePHAR’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • PHAR’s FA Score: 1 green, 4 red.
According to our system of comparison, PHAR is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish.

  • ATXS’s TA Score: 4 bullish, 4 bearish.

Price Growth

ATXS (@Biotechnology) experienced а +28.96% price change this week, while PHAR (@Biotechnology) price change was +6.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

PHAR is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAR($581M) has a higher market cap than ATXS($294M). PHAR YTD gains are higher at: -14.754 vs. ATXS (-41.723). PHAR has higher annual earnings (EBITDA): 7.56M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. PHAR (172M). ATXS has less debt than PHAR: ATXS (5.35M) vs PHAR (127M). PHAR has higher revenues than ATXS: PHAR (286M) vs ATXS (0).
ATXSPHARATXS / PHAR
Capitalization294M581M51%
EBITDA-111.56M7.56M-1,476%
Gain YTD-41.723-14.754283%
P/E RatioN/AN/A-
Revenue0286M-
Total Cash328M172M191%
Total Debt5.35M127M4%
FUNDAMENTALS RATINGS
ATXS: Fundamental Ratings
ATXS
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
91
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATXS
RSI
ODDS (%)
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
MACD
ODDS (%)
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYBKX82.76N/A
N/A
Rydex Banking A
SSTFX9.73N/A
N/A
Virtus KAR Capital Growth C
ALSAX8.32N/A
N/A
Alger Small Cap Growth A
MFRKX52.28N/A
N/A
MFS Research R6
NRMGX15.62N/A
N/A
Neuberger Berman Mid Cap Growth R6

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+0.19%
TRDA - ATXS
52%
Loosely correlated
+2.87%
KYMR - ATXS
52%
Loosely correlated
+9.32%
XENE - ATXS
49%
Loosely correlated
+1.62%
APGE - ATXS
49%
Loosely correlated
+1.42%
DNLI - ATXS
49%
Loosely correlated
+4.17%
More

PHAR and

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
+3.75%
APLM - PHAR
31%
Poorly correlated
+0.40%
ADPT - PHAR
27%
Poorly correlated
+6.91%
IBRX - PHAR
27%
Poorly correlated
N/A
ATXS - PHAR
26%
Poorly correlated
+0.19%
SONN - PHAR
25%
Poorly correlated
-4.23%
More